Preclinical and clinical development of DNA vaccines for prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 34, Issue 4, 2016, Pages 193-204

  Colluru, V T ^a   Johnson, Laura E ^a   Olson, Brian M ^a   McNeel, Douglas G ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Clinical trials; DNA vaccines; Prostate cancer; Tumor vaccine

Indexed keywords

CD86 ANTIGEN; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECFIC MEMBRANE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNIZATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ANIMAL; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, DNA;

EID: 84961202366     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.014     Document Type: Review

References (60)

1. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
2. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
3. Ishii K.J., Kawagoe T., Koyama S., et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451:725-729.
4. Johnson L.E., Frye T.P., Chinnasamy N., Chinnasamy D., McNeel D.G. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+T cells. Cancer Immunol Immunother 2007, 56:885-895.
5. Alonso M., Leong J.A. Licensed DNA vaccines against infectious hematopoietic necrosis virus (IHNV). Recent Patents DNA Gene Seq 2013, 7:62-65.
6. Hall R.A., Khromykh A.A. West Nile virus vaccines. Expert Opin Biol Ther 2004, 4:1295-1305.
7. Grosenbaugh D.A., Leard A.T., Bergman P.J., et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011, 72:1631-1638.
8. Pavlenko M., Roos A.K., Lundqvist A., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004, 91:688-694.
9. Miller A.M., Ozenci V., Kiessling R., Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 2005, 28:389-395.
10. Roos A.K., Pavlenko M., Charo J., Egevad L., Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005, 62:217-223.
11. Mincheff M., Tchakarov S., Zoubak S., et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000, 38:208-217.
12. Gregor P.W., Pedraza A., Orlandi F., et al. A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)-A phase I trial of proof of principle. J Clin Oncol 2007, 25:3073S.
13. Chudley L., McCann K., Mander A., et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012, 61:2161-2170.
14. McNeel D.G., Dunphy E.J., Davies J.G., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054.
15. Becker J.T., Olson B.M., Johnson L.E., Davies J.G., Dunphy E.J., McNeel D.G. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010, 33:639-647.
16. Becker J.T., Johnson L.E., Liu G., Olson B.M., McNeel D.G. Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer. J Clin Oncol 2013, 31:135S.
17. Gnjatic S., Altorki N.K., Tang D.N., et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 2009, 15:2130-2139.
18. Roos A.K., Eriksson F., Timmons J.A., et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009, 4:e7226.
19. Johnson L.E., Frye T.P., Arnot A.R., et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006, 24:293-303.
20. Wolchok J.D., Gregor P.D., Nordquist L.T., Slovin S.F., Scher H.I. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003, 30:659-666.
21. Johnson L.E., Frye T.P., McNeel D.G. Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology 2012, 1:1546-1556.
22. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
23. Cheever M.A., Allison J.P., Ferris A.S., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15:5323-5337.
24. Kantoff P.W., Schuetz T.J., Blumenstein B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
25. Naslund T.I., Uyttenhove C., Nordstrom E.K., et al. Comparative prime-boost vaccinations using semliki forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol 2007, 178:6761-6769.
26. Garcia-Hernandez Mde L., Gray A., Hubby B., Kast W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007, 67:1344-1351.
27. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999, 5:287-300.
28. Lai M.D., Yen M.C., Lin C.M., et al. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genet Vaccines Ther 2009, 7:2.
29. Ito K., Shinohara N., Kato S. DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response. Mol Immunol 2003, 39:847-854.
30. Olson B.M., Johnson L.E., McNeel D.G. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother 2013, 62:585-596.
31. Smith H.A., McNeel D.G. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother 2011, 34:569-580.
32. Staff C., Mozaffari F., Haller B.K., Wahren B., Liljefors M.A. Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine 2011, 29:6817-6822.
33. Degl'Innocenti E., Grioni M., Boni A., et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005, 35:66-75.
34. Gulley J.L., Drake C.G. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011, 17:3884-3891.
35. Madan R.A., Gulley J.L., Fojo T., Dahut W.L. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010, 15:969-975.
36. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007, 25:1765-1771.
37. Aragon-Ching J.B., Williams K.M., J.L.Gulley Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007, 12:4957-4971.
38. Drake C.G., Doody A.D., Mihalyo M.A., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7:239-249.
39. Akins E.J., Moore M.L., Tang S., Willingham M.C., Tooze J.A., Dubey P. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res 2010, 70:3473-3482.
40. Morse M.D., McNeel D.G. Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum Immunol 2010, 71:496-504.
41. Antonarakis E.S., Kibel A.S., Adams G., et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results. J Clin Oncol 2013, [suppl; abstr 5016].
42. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
43. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008, 222:357-368.
44. Klencke B., Matijevic M., Urban R.G., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 2002, 8:1028-1037.
45. Timmerman J.M., Singh G., Hermanson G., et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002, 62:5845-5852.
46. Norell H., Poschke I., Charo J., et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010, 8:53.
47. Conry R.M., Curiel D.T., Strong T.V., et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002, 8:2782-2787.
48. Victora G.D., Socorro-Silva A., Volsi E.C., et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 2009, 16:598-608.
49. Ginsberg B.A., Gallardo H.F., Rasalan T.S., et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res 2010, 16:4057-4065.
50. Yuan J., Ku G.Y., Gallardo H.F., et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009, 9:5.
51. Wolchok J.D., Yuan J., Houghton A.N., et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007, 15:2044-2050.
52. Triozzi P.L., Aldrich W., Allen K.O., Carlisle R.R., LoBuglio A.F., Conry R.M. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 2005, 28:382-388.
53. Weber J., Boswell W., Smith J., et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008, 31:215-223.
54. Dangoor A., Lorigan P., Keilholz U., et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol Immunother 2010, 59:863-873.
55. Cassaday R.D., Sondel P.M., King D.M., et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007, 13:540-549.
56. Nabel G.J., Gordon D., Bishop D.K., et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996, 93:15388-15393.
57. Tagawa S.T., Lee P., Snively J., et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 2003, 98:144-154.
58. Rosenberg S.A., Yang J.C., Sherry R.M., et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 2003, 14:709-714.
59. Nemunaitis J., Meyers T., Senzer N., et al. Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006, 13:1185-1191.
60. Weber J.S., Vogelzang N.J., Ernstoff M.S., et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 2011, 34:556-567.